Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Net Cash Flow (2016 - 2025)

Cumberland Pharmaceuticals' Net Cash Flow history spans 16 years, with the latest figure at -$3.8 million for Q4 2025.

  • For Q4 2025, Net Cash Flow fell 851.27% year-over-year to -$3.8 million; the TTM value through Dec 2025 reached -$6.5 million, down 1723.94%, while the annual FY2025 figure was -$6.5 million, 1723.94% down from the prior year.
  • Net Cash Flow for Q4 2025 was -$3.8 million at Cumberland Pharmaceuticals, down from -$890536.0 in the prior quarter.
  • Across five years, Net Cash Flow topped out at $1.3 million in Q3 2022 and bottomed at -$9.8 million in Q1 2022.
  • The 5-year median for Net Cash Flow is $169129.0 (2021), against an average of -$1.0 million.
  • The largest YoY upside for Net Cash Flow was 666.9% in 2022 against a maximum downside of 5879.04% in 2022.
  • A 5-year view of Net Cash Flow shows it stood at -$796737.0 in 2021, then surged by 127.16% to $216432.0 in 2022, then crashed by 1657.9% to -$3.4 million in 2023, then surged by 114.81% to $499430.0 in 2024, then plummeted by 851.27% to -$3.8 million in 2025.
  • Per Business Quant, the three most recent readings for CPIX's Net Cash Flow are -$3.8 million (Q4 2025), -$890536.0 (Q3 2025), and $978868.0 (Q2 2025).